Stockreport

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update

Nasus Pharma Ltd. Ordinary Shares  (NSRX) 
PDF Recent Phase 2 topline results demonstrate NS002’s potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption comp [Read more]